Therapeutic Benefits Of Wyeth To Pfizer
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Therapeutic Benefits Of Wyeth To Pfizer

on

  • 4,038 views

A comparative study of Pfizer\'s opportunities form Wyeth;s product portfolio

A comparative study of Pfizer\'s opportunities form Wyeth;s product portfolio

Statistics

Views

Total Views
4,038
Views on SlideShare
4,020
Embed Views
18

Actions

Likes
0
Downloads
83
Comments
1

4 Embeds 18

http://www.slideshare.net 9
http://www.linkedin.com 5
http://www.lmodules.com 3
https://www.linkedin.com 1

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
  • nice...
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Therapeutic Benefits Of Wyeth To Pfizer Presentation Transcript

  • 1. Therapeutic benefits of Wyeth to Pfizer Ritupon Gogoi , B. Pharm, MBA
  • 2. Key diseases Marketed products Pipeline Benefits Risks Alzheimer’s Strong pipeline Market Dominance Anti-competitive market dominance Inflammation Enbrel TRU-015 Small molecule + biological therapy Oncology Torisel Niche indications Bulking-up portfolio Diabetes Weak pipeline Pain Schizophrenia None None None Infectious diseases Prevnar Prevnar 13; meningitis New area; steady revenues Biologics culture at risk Women’s Health Premarin; Prempro Aprela Market dominance in HRT; entry to osteoporosis Market dominance in HRT Source: Datamonitor Strongly positive Positive None Negative Synergies Vaccines CORE
  • 3. P&P- Pfizer & Problems
    • Since Pfizer’s acquisition of Warner-Lambert in 2000 and Pharmacia in 2003, Pfizer has found it increasingly difficult to develop new drug candidate in-house.
    • Management focused on the integration of companies acquired rather than on the development of new drug.
    • Led to the dearth of late-stage pipeline candidates to replace Lipitor.
    • Pfizer’s pipeline also had to deal with the major blow of the failure of Torcetrapid in late 2006 because of side-effect concerns .
  • 4. Benefits of Wyeth to Pfizer
    • Wyeth will bring to Pfizer a number of marketed products and pipeline candidates but is unlikely to address the fundamental loss of loss of R&D productivity.
    • Pfizer has identified six high-potential disease areas that would provide the company’s future growth: oncology, pain, inflammation, diabetes, Alzheimer’s disease and schizophrenia.
    • The acquisition of Wyeth strengthens Pfizer’s position in a number of these key disease areas, notably Alzheimer’s disease and inflammation.
    • The long term prospects of the oncology portfolio are also strengthened.
  • 5. Benefits of Wyeth to Pfizer Alzheimer’s growing market
    • The merger will have little effect on the other key disease areas of pain, psychiatry (schizophrenia) and diabetes.
    • Pfizer has the most to gain in Alzheimer’s disease.
    • Alzheimer’s disease market growth will reach $10 billion in seven major markets (US, Japan, France, Germany, Italy, Spain and UK) in 2017*.
    • The potential disease-slowing therapies bapineuzumabs (Elan/Wyeth) and Dimebon (Medivation/Pfizer) are expected to be the main drivers of growth in the Alzheimer’s market over the next five years.
    • The Pfizer-Wyeth combination would dominate the Alzheimer’s pipeline with a total of 15 candidates in development, but as many of these projects are novel, there is high risk of clinical trial failure.
    • * Source: Datamonitor
    Cont…
  • 6. Benefits of Wyeth to Pfizer Opportunities in inflammation and vaccines
    • The merger offers the opportunities to bring Pfizer’s Celebrex (celecoxib) and Wyeth/Amgen’s Enbrel (etanercept) into the same portfolio for the treatment of rheumatoid arthritis.
    • Celebrex has patent protection in the US until 2014 and Enbrel is due to lose US patent protection in 2011.
    • Enbrel may not face generic competition for some time after 2011 as the drug is a fusion protein and its approval was completed through a biologic license application (BLA) in US.
    • The regulatory pathway for biosimilars has yet to be approved in the US.
    Cont…
  • 7. Benefits of Wyeth to Pfizer Opportunities in inflammation and vaccines
    • The merger Pfizer-Wyeth pipelines also offer a dual biologic and smaller molecule approach to the next generation of rheumatoid arthritis therapies.
    • Wyeth is developing the fusion-protein TRU-015 in collaboration with Trubion Pharmaceuticals.
    • While Pfizer has focused on small molecule with the first-in-class Janus kinase – 3(JAK-3) inhibitor CP-690550.
    • Two other areas where Wyeth will significantly add to Pfizer’s portfolio are in infectious disease vaccines and in antibiotics.
    Cont…
  • 8. Benefits of Wyeth to Pfizer Opportunities in inflammation and vaccines
    • Pfizer will now become one of the leading vaccine manufacturers through accessing Wyeth’s vaccines portfolio.
    • Long neglected by drug companies as low-margins therapies, the vaccines market was transformed by the launch of Wyeth’s pneumococcal vaccine Prevnar in 2000.
    • Wyeth has focused heavily on Prevnar and Prevnar-13, to the detriment of its development pipeline, resulting in only its Phase II meningitis B vaccine (MnBrLP2086) showing significant market potential.
    • Both Pfizer and Wyeth have a strong presence in hospital antibiotics with revenues of $2.5billion in the seven major markets in 2007 from Zyvox (Pfizer’s linezolid), Tygacil (Wyeth tigecycline) and Zosyn.
    Cont…
  • 9. Pfizer-Wyeth: Conclusion
    • To counter the commercial threat posed by Lipitor’s looming patent expiry, Pfizer has once again ceded to the lure of increased scale via M&A activity, in many ways this has become the only means by which Pfizer can appease investors following its expansion over the past decade, driven by previous mergers with Warner-Lambert and Pharmacia.
    • The acquisition of Wyeth could well be the first in a number of new purchases as Pfizer remains weak in diabetes and schizophrenia and still lacks critical mass in oncology.